Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Cosentyx Drug Market Size Forecast: How Large Could The Market Become By 2030?
The cosentyx drug market has seen robust expansion in recent times. Projected to increase from $5.68 million in 2025 to $6.21 million in 2026, the compound annual growth rate is 9.2%. Factors driving historical growth include the authorization of IL-17 inhibitors, a high incidence of psoriasis and arthritis, inadequate responses to TNF inhibitors, uptake by dermatology specialists, and the establishment of biologic treatment protocols.
The market for Cosentyx is anticipated to experience robust expansion in the coming years, with projections indicating it will reach a value of $8.74 million by 2030, reflecting a compound annual growth rate (CAGR) of 8.9%. Factors driving this forecasted growth include a rise in autoimmune disease diagnoses, an extension of approved treatment indications, heightened patient awareness, improved access to biologic therapies, and the backing of long-term efficacy data. Key developments shaping the forecast period encompass an increasing preference for IL-17 inhibitor therapies, the broadening of their application across various autoimmune conditions, a transition towards more targeted biologic options, a greater emphasis on long-term maintenance treatment, and a growing need for self-administered injectable biologics.
Download A Free Sample Report For Comprehensive Market Insights:
Cosentyx Drug Market Growth Drivers And Industry Catalysts
The anticipated growth of the cosentyx market is being driven by an increasing incidence of autoimmune diseases. These conditions occur when the immune system erroneously attacks the body’s own healthy cells and tissues. Factors contributing to this rise include genetic susceptibility, environmental triggers like infections and pollutants, and lifestyle modifications such as heightened stress levels and dietary changes. Cosentyx, also known as secukinumab, assists patients with autoimmune disorders by specifically blocking interleukin-17A, a crucial cytokine in inflammatory pathways, thus alleviating symptoms, enhancing quality of life, and effectively treating ailments like psoriasis, psoriatic arthritis, and ankylosing spondylitis. To illustrate, Public Health Scotland, a national organization based in Scotland, reported in August 2024 that the Scottish Multiple Sclerosis Register documented 455 new MS diagnoses in 2023. Consequently, the growing prevalence of autoimmune diseases is fueling the cosentyx market.
Cosentyx Drug Market Driver: Rising Healthcare Expenditure Expected To Enhance Cosentyx Drug
Expanding healthcare spending is set to accelerate the growth of the cosentyx market in the near future. Healthcare expenditure encompasses all financial outlays for medical goods and services, covering personal care, preventive measures, and public health initiatives designed to improve health results over a given timeframe. This upward trend in spending stems from factors like an aging demographic, the prevalence of chronic illnesses, cutting-edge medical equipment, elevated medication costs, inefficient reimbursement systems, and a growing need for healthcare services. Funding allocated for Cosentyx mainly goes toward controlling moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis, boosting patient outcomes through targeted biologic treatment. For example, a report from the Office for National Statistics, a UK government agency, released in May 2024 indicated that total healthcare expenditures increased by 5.6% in nominal terms from 2022 to 2023, contrasting with a 0.9% growth rate in 2022. Thus, escalating healthcare expenditure is propelling the cosentyx market forward.
Cosentyx Drug Market Segmentation Trends And Revenue Drivers
The cosentyx drug market covered in this report is segmented –
1) By Indication: Hidradenitis suppurativa, Psoriatic arthritis, Ankylosing spondylitis, Plaque Psoriasis
2) By Route Of Administration: Subcutaneous injection, Intravenous infusion
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
Cosentyx Drug Market Trends Influencing Long-Term Demand
Within the cosentyx drug market, major industry players are actively pursuing the creation of advanced therapies, particularly biologic treatments, to tackle unmet medical needs. These efforts are focused on improving treatment effectiveness, delivering precise therapeutic interventions for chronic autoimmune diseases, and ultimately strengthening their competitive standing while serving an expanding patient base. Biologic therapies, which are sophisticated treatments sourced from living organisms or their cellular components, work by specifically targeting immune system elements like interleukin-17A. This action helps regulate inflammatory responses and provides effective management for autoimmune disorders including psoriasis, psoriatic arthritis, and ankylosing spondylitis. A notable example occurred in October 2023 when Novartis AG, a pharmaceutical company based in Switzerland, secured FDA approval for Cosentyx, known generically as secukinumab, as the first novel biologic therapy in nearly a decade for treating moderate to severe hidradenitis suppurativa. This regulatory milestone represents a substantial leap forward in managing HS, a chronic and often debilitating skin disease that presents with painful nodules, frequently resulting in scarring and significant psychological burden.
Cosentyx Drug Market Industry Leaders: Which Organizations Are Driving Competition?
Major companies operating in the cosentyx drug market are Novartis AG
Access The Complete Cosentyx Drug Market Report:
Cosentyx Drug Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the cosentyx drug market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cosentyx drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model